RGS16 overexpression in breast cancer cells inhibits the cell prolife ration dependent on epidermal growth factor (EGF), and decreased RGS16 expression was associated with a reduction in the cell proliferation rate and an increased resistance to tyrosine kinase inhibitors. This evidence concerns the gene RGS16 and breast carcinoma.